Pyrazolinone analgesics prevent the antiplatelet effect of aspirin and preserve human platelet thromboxane synthesis

Journal of Thrombosis and Haemostasis

Volumn 6, Issue 1, 2008, Pages 166-173

  Hohlfeld, Thomas ^a   Zimmermann, N ^a   Weber, A A ^b   Jessen, G ^c   Weber, H ^c   Schror K ^a   Holtje H D ^c   Ebel, R ^c  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Aspirin; Cyclooxygenase; Dipyrone; Drug interaction; Platelets; Pyrazolinone analgesics

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; ARACHIDONIC ACID; COLLAGEN; CYCLOOXYGENASE 1; DIPYRONE; IBUPROFEN; LUMINOL; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; NORAMIDOPYRINE; PADGEM PROTEIN; PROSTAGLANDIN SYNTHASE; PYRAZOLINONE DERIVATIVE; THROMBOXANE; UNCLASSIFIED DRUG;

ARTICLE; CARDIOVASCULAR DISEASE; CELL FREE SYSTEM; COMPETITIVE INHIBITION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG ACTIVITY; ENZYME INHIBITION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LUMINESCENCE; MICROSOME; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE RICH PLASMA;

ANALGESICS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; BINDING SITES; BLOOD PLATELETS; CELLS, CULTURED; CYCLOOXYGENASE 1; DIPYRONE; DRUG ANTAGONISM; HUMANS; PLATELET AGGREGATION; PYRAZOLONES; THROMBOXANES;

EID: 37549014900     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2007.02800.x     Document Type: Article

References (40)

1. Weber A-A, Przytulski B, Schanz A, Hohlfeld T, Schrör K. Towards a definition of aspirin resistance: A typological approach. Platelets 2002; 13: 37-40.
2. Michelson AD, Cattaneo M, Eikelboom JW, Gurbel P, Kottke-Marchant K, Kunicki TJ, Pulcinelli FM, Cerletti C, Rao AK. Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J Thromb Haemost 2005; 3: 1309-11.
3. Schrör K, Weber AA, Hohlfeld T. Aspirin 'resistance'. Blood Cells Mol Dis 2006; 95: 505-10.
4. Livio M, Del Maschio A, Cerletti C, De Gaetano G. Indomethacin prevents the long-lasting inhibitory effect of aspirin on human platelet cyclo-oxygenase activity. Prostaglandins 1982; 23: 787-96.
5. Capone ML, Sciulli MG, Tacconelli S, Grana M, Ricciotti E, Renda G, Di Gregorio P, Merciaro G, Patrignani P. Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. J Am Coll Cardiol 2005; 45: 1295-301.
6. Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, Vyas SN, FitzGerald GA. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001; 345: 1809-17.
7. Grotemeyer KH, Scharafinski HW, Husstedt IW. Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients. Thromb Res 1993; 71: 397-403.
8. Mueller MR, Salat A, Stangl P, Murabito M, Pulaki S, Boehm D, Koppensteiner R, Ergun E, Mittlboeck M, Schreiner W, Losert U, Wolner E. Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost 1997; 78: 1003-7.
9. Gæde P, Vedel P, Larsen N, Jensen GVH, Parving H-H, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. New Engl J Med 2003; 348: 383-39.
10. Biondi-Zoccai GG, Lotrionte M, Agostoni P, Abbate A, Fusaro M, Burzotta F, Testa L, Sheiban I, Sangiorgi G. A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50279 patients at risk for coronary artery disease. Eur Heart J 2006; 27: 2667-74.
11. Ho PM, Spertus JA, Masoudi FA, Reid KJ, Peterson ED, Magid DJ, Krumholz HM, Rumsfeld JS. Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med 2006; 166: 1842-7.
12. Farkouh ME, Greenberg JD, Jeger RV, Ramanathan K, Verheugt FW, Chesebro JH, Kirshner H, Hochman JS, Lay CL, Ruland S, Mellein B, Matchaba PT, Fuster V, Abramson SB. Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib. Ann Rheum Dis 2007; 66: 764-70.
13. Pierre SC, Schmidt R, Brenneis C, Michaelis M, Geisslinger G, Scholich K. Inhibition of cyclooxygenases by dipyrone. Br J Pharmacol 2007; 151: 494-503.
14. Campos C, de Gregorio R, Garcia-Nieto R, Gago F, Ortiz P, Alemany S. Regulation of cyclooxygenase activity by metamizol. Eur J Pharmacol 1999; 378: 339-47.
15. Censarek P, Freidel K, Udelhoven M, Ku SJ, Hohlfeld T, Meyer-Kirchrath J, Schrör K, Weber AA. Cyclooxygenase COX-2a, a novel COX-2 mRNA variant, in platelets from patients after coronary artery bypass grafting. Thromb Haemost 2004; 92: 925-8.
16. Weber A-A, Liesener S, Schanz A, Hohlfeld T, Schrör K. Habitual smoking causes an abnormality in platelet thromboxane A 2 metabolism and results in an altered susceptibility to aspirin effects. Platelets 2000; 11: 177-82.
17. Zimmermann N, Wenk A, Kim U, Kienzle P, Weber AA, Gams E, Schrör K, Hohlfeld T. Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery. Circulation 2003; 108: 542-7.
18. Stein E, Trachte GJ. Thromboxane A2 augments adrenergic neurotransmission. Eicosanoids 1990; 3: 205-11.
19. Forghani F, Ouellet M, Keen S, Percival MD, Tagari P. Analysis of prostaglandin G/H synthase-2 inhibition using peroxidase-induced luminol luminescence. Anal Biochem 1998; 264: 216-21.
20. Weber A-A, Braun M, Hohlfeld T, Schwippert B, Tschöpe D, Schrör K. Recovery of platelet function after discontinuation of clopidogrel treatment in healthy volunteers. Br J Clin Pharmacol 2001; 52: 333-6.
21. Goodford PJ. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. J Med Chem 1985; 28: 849-57.
22. Lindahl B, Hess B, van der Spoel D. GROMACS 3.0: A package for molecular simulation and trajectory analysis. J Mol Model 2001; 7: 306-17.
23. Geisslinger G, Peskar BA, Pallapies D, Sittl R, Levy M, Brune K. The effects on platelet aggregation and prostanoid biosynthesis of two parenteral analgesics: Ketorolac tromethamine and dipyrone. Thromb Haemost 1996; 76: 592-7.
24. Hinz B, Cheremina O, Bachmakov J, Renner B, Zolk O, Fromm MF, Brune K. Dipyrone elicits substantial inhibition of peripheral cyclooxygenases in humans: New insights into the pharmacology of an old analgesic. FASEB J 2007; 21: 2343-51.
25. Andre P. P-selectin in haemostasis. Br J Haematol 2004; 126: 298-306.
26. Assadian A, Lax J, Meixner-Loicht U, Hagmuller GW, Bayer PM, Hubl W. Aspirin resistance among long-term aspirin users after carotid endarterectomy and controls: Flow cytometric measurement of aspirin-induced platelet inhibition. J Vasc Surg 2007; 45: 1142-7.
27. Ouellet M, Riendeau D, Percival MD. A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin. Proc Natl Acad Sci USA 2001; 98: 14583-8.
28. Wong S, Morel-Kopp MC, Chen Q, Appleberg M, Ward CM, Lewis DR. Overcoming aspirin resistance: Increased platelet inhibition with combination aspirin and clopidogrel and high dose aspirin therapy in aspirin resistant patients with peripheral vascular disease. Thromb Haemost 2006; 95: 1042-3.
29. Pulcinelli FM, Riondino S, Celestini A, Pignatelli P, Trifiro E, Di Renzo L, Violi F. Persistent production of platelet thromboxane A2 in patients chronically treated with aspirin. J Thromb Haemost 2005; 3: 2784-9.
30. Jedlitschky G, Tirschmann K, Lubenow LE, Nieuwenhuis HK, Akkerman JW, Greinacher A, Kroemer HK. The nucleotide transporter MRP4 (ABCC4) is highly expressed in human platelets and present in dense granules, indicating a role in mediator storage. Blood 2004; 104: 3603-10.
31. El Sheikh AA, van den Heuvel JJ, Koenderink JB, Russel FG. Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP) 2/ABCC2- and MRP4/ABCC4-mediated methotrexate transport. J Pharmacol Exp Ther 2007; 320: 229-35.
32. Smith T, Leipprandt J, DeWitt D. Purification and characterization of the human recombinant histidine-tagged prostaglandin endoperoxide H synthases-1 and -2. Arch Biochem Biophys 2000; 375: 195-200.
33. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 1994; 330: 1287-94.
34. Loll PJ, Picot D, Garavito RM. The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase. Nat Struct Biol 1995; 2: 637-43.
35. Wessel JC, Matyja M, Neugebauer M, Kiefer H, Daldrup T, Tarbah FA, Weber H. Characterization of oxalic acid derivatives as new metabolites of metamizol (dipyrone) in incubated hen's egg and human. Eur J Pharm Sci 2006; 28: 15-25.
36. Vazquez E, Hernandez N, Escobar W, Vanegas H. Antinociception induced by intravenous dipyrone (metamizol) upon dorsal horn neurons: Involvement of endogenous opioids at the periaqueductal gray matter, the nucleus raphe magnus, and the spinal cord in rats. Brain Res 2005; 1048: 211-7.
37. Laporte JR, Carne X, Vidal X, Moreno V, Juan J. Upper gastrointestinal bleeding in relation to previous use of analgesics and non-steroidal anti-inflammatory drugs. Catalan Countries Study on Upper Gastrointestinal Bleeding. Lancet 1991; 337: 85-9.
38. Abbate R, Pinto S, Gori AM, Paniccia R, Coppo M, Neri Serneri GG. Activity of dipyrone on intraplatelet arachidonic acid metabolism: An in vitro study. Pharmacol Res 1989; 21: 43-50.
39. Nink K, Schröder H. Ergänzende statisitsche Übersicht. In: Schwabe U, Paffrath D, eds. Arzneiverordnungsreport 2006. Heidelberg, Germany: Springer, 2006: 1017.
40. Garcia S, Canionero M, Lopes G. Dipyrone-induced granulocytopenia: A case for awareness. Pharmacotherapy 2006; 26: 440-2.